支气管哮喘患者应用布地奈德福莫特罗干粉吸入剂联合督导方法治疗的临床效果

目的:探讨布地奈德福莫特罗干粉吸入剂联合督导方法治疗支气管哮喘的临床效果。方法:选取2012年11月至2015年11月期间来江阴医院进行治疗的138例支气管哮喘患者,随机分成观察组与对照组,对照组采用布地奈德福莫特罗干粉吸入剂,观察组采用布地奈德福莫特罗干粉吸入剂和督导方法,比较两组患者的临床效果。结果:两组患者治疗前和治疗后9周的哮喘基本控制率相比较,两组支气管哮喘患者治疗后3周和6周的哮喘基本控制率相比较,两组间的差异具有统计学意义;两组患者治疗3个月后的肺活量(FEV1)和气高峰流量(PEF)与治疗前相比较,两组患者治疗3个月后的FEV1和PEF与对照组相比较,组间的差异均具有统计学意义;观察组患者治疗后不良反应发生率(11.5%)明显低于对照组(14.4%),两组间的差异无统计意义。结论:布地奈德福莫特罗干粉吸入剂联合督导方法可以明显改善患者的支气管哮喘临床症状、肺功能以及患者的生活质量,具有较好的安全性。

Clinical efficacy of Supervising the Usage Method of Budesonide and Formoterol Fumarate Powder for Inhalation for the treatment of patients with bronchial asthma

Objective: To investigate clinical efifcacy of Supervising the Usage Method of Budesonide and Formoterol Fumarate Powder for Inhalation for the treatment of patients with bronchial asthma.Methods:During the period from 2012 November to 2015 November, 138 cases of bronchial asthma patients admitted to our hospital were selected and randomly divided into observation group and control group. The patients in control group were treated with budesonide and formoterol fumarate powder for inhalation and the patiens in observation group were additionally supervised on the usage method of above drug. Clinical efifcacy was compared between the two groups.Results: Threre were signiifcant differences in basic asthma control rates between pre-treatment and 3 weeks, 6 weeks, 9 weeks and 3 months after treatment for both two groups as well as between two groups. Threre were also signiifcant differences in FEV1 and PEF between pre-treatment and 3 months after treatment for both two groups as well as between two groups. The incidence of adverse reactions was signiifcantly lower in observation group patients (11.5%) than the control group (14.4%) without statistically signiifcant difference. Conclusion: Budesonide and formoterol fumarate powder for inhalation in combination with supervision method can signiifcantly improve clinical symptoms, lung function and patient's quality of life with better security in the treatment of patients with bronchial asthma.